EBEby P. Baby

Eby P. Baby

*This is an algorithmically generated author record based on publicly available information.

Eby P. Baby has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical outcomes and health-system challenges in congenital afibrinogenemia: a single-centre prospective case series

    by Nita Radhakrishnan, Savitri Singh, Archit Pandharipande, Eby P. Baby, Hari Gaire

  • Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries

    by Archit S. Pandharipande, Silky Jain, Anuj Singh, Shruti Verma, Eby P. Baby, Hari Gaire, Sudipto Bhattacharya, Aditi Tulsiyan, Savitri Singh, Nita Radhakrishnan

    Introduction The real-world data on treatment and outcome of hemophilia patients using extended half-life products in developing countries remain scarce. This is largely due to delayed diagnosis, poor joint outcomes, increased morbidity, and limited access to prophylaxis and newer products for treatment and prevention. Aim To analyze the response to extended half-life factor (EHL) prophylaxis in patients with severe hemophilia A and B with advanced arthropathy. Methods Patients with severe hemophilia A and B who received EHL factor concentrates for prophylaxis at our center were included in this analysis. Data collected included bleed frequency, joint involvement, annualized bleed rate (ABR), number of hospital visits, and Hemophilia Joint Health Score (HJHS) prior to prophylaxis. Breakthrough bleeds while on prophylaxis were also recorded. Results A total of 31 patients were started on EHL prophylaxis and followed up for a period ranging from 4 to 91 weeks. A reduction in the bleeding rate was noticed in all with significant reversal of target joints. Additionally, patients remained bleed-free during rehabilitation following joint surgery as well as psoas bleed-related compression neuropathy. Conclusion EHL prophylaxis appears to be an effective strategy even for patients with baseline target joints with significant arthropathy, thus reducing the extent of disability in these patients.

  • Open Access

    Barriers to cascade screening and prenatal testing in families with genetic haematological diseases

    by Archit Pandharipande, Nita Radhakrishnan, Shruti Verma, Vivek Kumar Chauhan, Eby P. Baby, Anukriti Srivastava

    Introduction: Cascade screening to identify at-risk relatives of patients with genetic conditions is a strong intervention to reducing the burden of genetic disorders. Even then, we often observe more than one child with same genetic hematological disease in the same family and evaluated reasons for this. Methods: The study was conducted between 1 June 2023 and 31 May 2024 at our outpatient service. A cross-sectional survey of families with more than one child with inherited hematological disorders such as hemophilia or thalassemia-major were enrolled. We analyzed demographic variables, awareness regarding disease, barriers, financial implications, and current opinion regarding carrier testing. Results: Out of more than 1200 inherited hematological diseases registered at our center, the first 50 families who had more than one child with the same disease (hemophilia 28, von Willebrand disease 4, afibrinogenemia 1, beta-thalassemia major 17 and sickle beta-thalassemia 1) were enrolled. Consanguinity was present in five families and endogamy in nine. Regarding family history, 12 had first or second-degree family members with the same disease in earlier generations. 47% parents had high-school education and 24% were graduates. None were aware of hemophilias or hemoglobinopathies before the birth of their index child. Only 27 families (54%) knew the hereditary nature of this illness. When enquired, 12 out of 50 families (24%) knew that this disease could recur in next pregnancy. Significant financial burden was reported for transportation costs and parental job absenteeism. All unanimously agreed to endorse carrier detection in family members. Conclusion: Cascade screening is a strong tool to prevent inherited hematological diseases. Counseling to allay the myths is needed to motivate families to proceed with carrier detection is a dire necessity.